NEW YORK (GenomeWeb News) – Qiagen today said that GE company Clarient will offer its therascreen KRAS RGQ PCR kit as a companion diagnostic.

Clarient will offer the test to help guide the use of Erbitux (cetuximab) for treating patients with metastatic colorectal cancer. Clarient chose the therascreen KRAS assay and Qiagen's Rotor-Gene Q molecular diagnostic platform after the US Food and Drug Administration approved the test in July, Qiagen said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.